[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy
Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …
frequent summaries of the current achievements in the field. In our review, we aimed to …
Epidermal growth factor receptor cell proliferation signaling pathways
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
A Ayati, S Moghimi, S Salarinejad, M Safavi… - Bioorganic …, 2020 - Elsevier
The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …
progression is considered as one of the most successful plans in cancer treatment. The …
Role of molecular dynamics and related methods in drug discovery
Molecular dynamics (MD) and related methods are close to becoming routine computational
tools for drug discovery. Their main advantage is in explicitly treating structural flexibility and …
tools for drug discovery. Their main advantage is in explicitly treating structural flexibility and …
Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors
The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs)
gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers …
gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers …
[HTML][HTML] Single nucleotide polymorphisms and cancer susceptibility
NA Deng, H Zhou, H Fan, Y Yuan - Oncotarget, 2017 - ncbi.nlm.nih.gov
A large number of genes associated with various cancer types contain single nucleotide
polymorphisms (SNPs). SNPs are located in gene promoters, exons, introns as well as 5' …
polymorphisms (SNPs). SNPs are located in gene promoters, exons, introns as well as 5' …
EGF receptor trafficking: consequences for signaling and cancer
A Tomas, CE Futter, ER Eden - Trends in cell biology, 2014 - cell.com
The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively
studied in the analysis of molecular mechanisms regulating endocytic traffic and the role of …
studied in the analysis of molecular mechanisms regulating endocytic traffic and the role of …
[HTML][HTML] Allostery in disease and in drug discovery
Allostery is largely associated with conformational and functional transitions in individual
proteins. This concept can be extended to consider the impact of conformational …
proteins. This concept can be extended to consider the impact of conformational …
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
S Wang, Y Song, D Liu - Cancer Letters, 2017 - Elsevier
The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686
(rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M …
(rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M …